Company Overview

GemPharmatech is a leading provider of genetically engineered mouse models (GEMMs) and services to global preclinical R&D communities. We specialize in developing animal models using cutting edge gene-editing technologies with a large collection of cKO/KO (conditional knockout/knockout) mice, humanized mice, immunodeficient mice, and germ-free mice. GemPharmatech provides an expansive array of preclinical services, including mouse model customization, pharmacology services such as drug efficacy testing and mouse phenotyping, CRISPR/Cas9 gene-editing, cryopreservation, rapid expansion, and customized breeding. The company has developed one of the world's largest collections of mouse models to enable scientific innovation and accelerate drug development.

Genetically Engineered Mouse Models Driving Innovation

Our History


GemPharmatech Co. Ltd. Founded

Parent company GemPharmatech Co. Ltd. established with headquarters in Nanjing, China.


Knockout All Project (KOAP) Initiated

Knockout All Project (KOAP) initiated to establish a comprehensive library of knockout (KO) and conditional knockout (cKO) mice for all protein coding genes in the mouse genome.


Humanized Model Development

Developed humanized animal models and opened a branch in Changzhou to expand production capacity.


GemPharmatech US Launched

Obtained germ-free animal production license, expanded production base by opening facilities in Chengdu and Guangzhou, and launched GemPharmatech LLC to serve the North American and European markets.


17,000+ Genetically Engineered Mouse Models

Library reached 17,000+ genetically engineered mouse models (GEMMs), expanded productdion capacity by opening facilities in Beijing, China.

Leadership Team

Mark W. Moore, Ph.D

Chief Executive Officer

Mark is a pioneer in the use of genetically modified mice for pharmaceutical and basic research. He has worked in immunology, oncology, animal model construction and gene editing. Before joining GemPharmatech, he was a co-founder and CSO of Deltagen, the first high-throughput gene KO and target development company, and later served as the Executive Director of the International Mouse Phenotyping Consortium (IMPC). He received his Ph.D. in Biology from Brandeis University studying antibody gene recombination using transgenic mice.

Andrew Graham

Chief Financial Officer

Andrew has spent his career in finance and accounting focused on Life Science organizations in Human Health and Agriculture. Prior to joining GemPharmatech, he was the CFO of AgBiome LLC and helped them raise over $100M. His CFO experience spans both public and private organizations with expertise in raising capital, development and modeling of strategic plans, restructuring, investor relations, corporate accounting, financial reporting, merger and acquisitions, audit, banking, treasury, risk management and financial systems.

Zhiying Li, PhD

Director, Life Science and Technology

Zhiying is a trained neuroscientist with a doctoral degree from Harvard University. She conducted her postdoctoral research at Rockefeller University. Prior to joining GemPharmatech, she worked at Taconic Biosciences, providing scientific support to both commercial products and scientific services. She is a firm believer in ethical use of research animals and their invaluable contribution to biomedical research for the benefit of human health.

Brook White

Senior Director, Sales and Marketing

Brook has held senior marketing executive positions in a number of life sciences companies and has over 20 years of experience in the industry. Her prior experience includes working with companies in clinical trial technology, the clinical CRO space, and CDMO space.  She is responsible for leading GemPharmatech’s marketing and sales operations in the US.

Steven J. Smith, PhD

Director, Business Development

Steve is a research scientist and business development professional with over 20 years of experience in biotech drug discovery and business development. Steve has designed and conducted research in therapeutic areas spanning oncology, metabolic diseases, neurodegenerative diseases, inflammation, and immunology, as well as built in vivo and in vitro systems for disease model research. Prior to GemPharmatech, Steve led business development at Glialogix Inc., which was acquired by Zogenix. Inc., and then returned to the lab bench to lead the development of models for exploring new therapeutics. Steve earned a Ph.D. and M.S. in Microbiology from North Carolina State University and B.S. in Biology from Beloit College.

Jeremy Steuhl

Director, Information Technology

Jeremy is a veteran of the US Navy, where he began his career as an Intelligence Analyst and developed his enthusiasm for Information Technology.  Prior to joining GemPharmatech, Jeremy was the head of global business applications at Taconic Biosciences, where he was responsible for leading international teams in the implementation and support of life science solutions.

Thomas Tribou

Advisor, European Market Strategy

Thomas has spent his career in sales helping companies develop their sales for domestic and overseas markets. Thomas has lived and worked in France, Spain, and the US and has studied at Skema Business school, Lille, France and INSEAD Fontainebleau, France. His prior experience includes selling to academic institutions as well as biotech, CRO, and pharmaceutical companies in Europe, the UK, Middle East, and Asia. He is developing a strategy for GemPharmatech sales operations in the EMEA region.

About Us | Genetically Engineered Mouse Models (GEMMs)